Sexually-transmitted infections (STIs) are a global public health concern and AMR is making them harder to treat. In particular, drug-resistant gonorrhoea is rapidly outpacing the development of new medicines. GARDP’s STI programme includes efforts to develop a new treatment for drug-resistant gonorrhoea, investigate new combinations of antibiotics to treat STIs, and ensure sustainable access strategies.
Globally, newborn deaths account for 44 percent of all deaths in children under-five. Newborns are at particular risk from drug-resistant infections, such as sepsis. GARDP’s neonatal sepsis programme aims to develop new antibiotic treatments and provide an evidence base for the use of existing and new antibiotics to tackle drug-resistant neonatal sepsis.
Infectious diseases such as pneumonia and sepsis are a leading cause of death and disability in children under-five. The situation is aggravated by growing drug-resistance. GARDP’s paediatric antibiotic programme aims to expedite the development of new, improved and adapted antibiotics to treat serious bacterial infections in children of all ages.
Antimicrobial memory recovery, evaluation and exploratory research
To tackle AMR, we need a range of antimicrobial treatments. Achieving this requires both revisiting previously abandoned programmes and exploratory research. GARDP has developed programmes in antimicrobial memory recovery and evaluation, and discovery and exploratory research as well as REVIVE an online space to educate and connect the antimicrobial R&D community.